After adjusting the dosage and conducting numerous clinical trials, Gemtuzumab ozogamicin was reapproved by the FDA in 2017 for use in newly diagnosed and relapsed/refractory CD33-positive acute myeloid leukemia patients (22, 23). This evidence concerns the gene CD33 and acute myeloid leukemia.